In a recent Pharmaceutical Technology article, Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania Perelman School of Medicine and co-inventor of the first CAR-T cell therapy Kymriah, spoke on the further development of CAR-T therapies.
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally, not including patients treated in clinical trials.
In terms of what’s next for CAR-T, Levine said, “I’m really excited about the first potential CRISPR approval because it represents two elements; the integration of new technology, and the availability in a generally underserved population. If I had to pick one [event], I think that would be the one that we can really celebrate as scientists and as patient advocates.”
Read the full article here.